Volume 67, Issue 5, Pages 1106-1108 (November 2017) Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection  Naoki Kawagishi, Goki Suda, Masahiro Onozawa, Megumi Kimura, Osamu Maehara, Jun Ito, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto  Journal of Hepatology  Volume 67, Issue 5, Pages 1106-1108 (November 2017) DOI: 10.1016/j.jhep.2017.04.008 Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Clinical courses of 5 patients with HBV-reactivation or detectable HBV DNA. Serial serum alanine transferase (ALT), HBV DNA, HCV RNA, and anti-HBs were analyzed. Two patients (A, B) were treated with sofosbuvir and ledipasvir for 12weeks; one patient (C) was treated with sofosbuvir and ribavirin for 12weeks. One patient (D) was treated with daclatasvir and asunaprevir for 24weeks. One patient (E) was treated with daclatasvir and asunaprevir, with subsequent combination therapy cessation due to ALT elevation at 3months after treatment initiation. Immunocompromised factors included HIV-coinfection, administration of immunosuppressive agents, and dialysis. ALT, alanine aminotransferase; HBV, hepatitis B virus; HCV, hepatitis C virus; anti-HBs, antibody to hepatitis B surface antigen. EOT, end of treatment. Journal of Hepatology 2017 67, 1106-1108DOI: (10.1016/j.jhep.2017.04.008) Copyright © 2017 European Association for the Study of the Liver Terms and Conditions